


RESVERLOGIX (TSX:RVX) IS A LATE-STAGE BIOTECHNOLOGY COMPANY WITH A NOVEL EPIGENETIC APPROACH TO REDUCING THE INCIDENCE OF MAJOR ADVERSE CARDIAC EVENTS (MACE) IN HIGH-RISK CARDIOVASCULAR PATIENTS. LEAD DRUG APABETALONE IS FULLY ENROLLED IN A PHASE 3 CLINICAL TRIAL CALLED BETONMACE

Resverlogix is developing safe, affordable, first-in-class epigenetic therapeutics for people with heart disease, diabetes, chronic kidney disease and other life-threatening illnesses. Lead drug candidate **apabetalone** is in a **Phase 3 clinical trial, BETonMACE**, which is fully enrolled - top line data is estimated for Q1 2019.




MULTI-MODAL PATHWAY MECHANISM

Apabetalone, a bromodomain extra-terminal (BET) protein inhibitor regulates the expression of genes and restores the function of pathways underlying the pathogenesis of **cardiovascular disease, type 2 diabetes mellitus and chronic kidney disease.**



✉ : ir@resverlogix.com
 ☎ : 403.254.9252
 🌐 : www.resverlogix.com
 🐦 : @Resverlogix_RVX






Epigenetics

While most people are familiar with the inheritance of genes via DNA from one generation to the next, the activity of these genes is actually determined by epigenetics, which literally means “on top of” genetics. DNA is considered the hardware of the human body, while epigenetics can be referred to as the software. DNA contains the code that tells our cells what to do, and this coded message is the same in every cell and does not change with time. However, our cells do not behave in the exact same way across time, particularly when disease is involved. Epigenetic changes to the DNA allow the message in the genes to be turned up or down like a dimmer switch, telling the cells which products to make more, or less of. During this process the DNA is not altered. The epigenetic control over the genetic message in the DNA underlies many diseases, and for this reason, epigenetics has become an exciting forefront for the discovery of new medicines.

APABETALONE (RVX-208) CLINICAL TRIAL HISTORY



- Phase 3 BETonMACE trial commenced Q4/15 for high-risk CVD patients with type 2 diabetes mellitus and low HDL. ~15% of the patients will also have CKD. BETonMACE is fully enrolled.
- Primary endpoint: time to first occurrence of Major Adverse Cardiac Events (MACE).
- Based on mechanistic data, we believe apabetalone treatment, or select BET inhibition, attenuates the pathological process that contributes to disease initiation and progression.

News Highlights

Sept. 4, 2018 - RVX presents at CTAD Asia
 Aug. 30, 2018 - RVX closes \$26 million private placement
 Aug. 22, 2018 - RVX supports ESC Epigenetics Symposium
 Aug. 7, 2018 - RVX announces 7th positive DMSB recommendation for phase 3 BETonMACE
 July 31, 2018 - RVX intends to pursue US listing

Future Events

Oct. 1-5: EASD 2018, Berlin
 Oct. 17-18: BIO Investor Forum 2018, San Francisco
 Oct. 23-28: ASN Kidney Week 2018, San Diego
 Oct. 24-27: CTAD 2018, Barcelona

Analysts

Beacon Securities: David M. Kideckel, PhD, MBA.
 Van Leeuwenhoek Research: Marcel Wijma, MSc.
 Zacks: John Vandermosten, CFA.

Financial Profile

- Shares O/S (MM): 187.8
 - Share Price: \$3.61
 - Market Cap (MM): ~\$678
 - 52 week low/high: \$1.11/\$4.31
 - Total Cash Raised (MM): ~\$449

Notes:
 *As at 09-SEPT-18
 *All figures in CAD\$